prima takes mabs to holland, page-2

Can't post full article as prob breaching copyright, but here's the rest:

BEGINS:

The agreement paves the way for further development of the Oncomab technology, to create Cripto-1 mAB as an immunotherapy treatment for cancers.

In Europe, Bioceros is a premier provider of pre-clinical development services for mABs and good manufacturing practice-ready protein-producing cell-lines generation (CHO and PER.C6).

Oncomabs Cripto-1 antibody binds to the Cripto-1 protein, which is found at high levels on the surface of a number of malignant tumour cells.

The protein facilitates growth of tumour cells and contributes to their spread.

Oncomabs antibody interferes with local development of a tumour and prevents distant seeding.

The antibody can be administered with chemotherapy drugs to have a more lethal effect.

The licensing agreement with Bioceros will be achieved with a 70% Prima, 30% Bioceros project split, and the work will be undertaken by Bioceros.

Prima managing director Martin Rogers said the parent company was delighted to have engaged a high-quality partner to license the development of Cripto-1.

He described Bioceros as an industry expert in its field and said Prima looked forward to seeing the benefits of the companys work with Cripto-1.

We look forward to seeing the benefits of their work with Cripto-1, as we continue to grow our business in the area of cancer immunotherapy treatments, he said.

Prima gained 0.9c or 10.1% to 9.8c by mid-afternoon on the swap of 11.4 million shares.

ENDS


Looks like it is probably an adjuvant therapy designed to enhance the action of existing chemotherapy measure for cancer therapy - but that is from a business report, not a medical perspective of course. And of course MR will be upbeat about the partnership, otherwise they wouldn't have got into bed with them - hope he's right.

Good to have more than 1 string to the bow!